{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:51:52Z","timestamp":1781711512961,"version":"3.54.5"},"reference-count":12,"publisher":"Norwegian Medical Association","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.23.0346","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:15:12Z","timestamp":1696230912000},"source":"Crossref","is-referenced-by-count":1,"title":["Start- og stoppkriterier for sv\u00e6rt dyre medisiner \u2013 spinal muskelatrofi som eksempel"],"prefix":"10.4045","volume":"143","author":[{"given":"Magnhild","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"\u00d8rstavik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Popperud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Ramm-Pettersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidun","family":"F\u00f8rde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"ref=1","unstructured":"Mercuri\u00a0E, Sumner\u00a0CJ, Muntoni\u00a0F et al. Spinal muscular atrophy. Nat Rev Dis Primers 2022; 8: 52. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35927425&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41572-022-00380-8"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Finkel\u00a0RS, Mercuri\u00a0E, Darras\u00a0BT et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377: 1723\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29091570&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1702752","DOI":"10.1056\/NEJMoa1702752"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Mercuri\u00a0E, Darras\u00a0BT, Chiriboga\u00a0CA et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378: 625\u201335. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29443664&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1710504","DOI":"10.1056\/NEJMoa1710504"},{"key":"ref=4","unstructured":"Nye metoder. Kriterier for behandling med nusinersen Spinraza for barn 0-18 \u00e5r. https:\/\/nyemetoder.no\/Documents\/Beslutninger\/Kriterier%20for%20behandling%20med%20nusinersen%20Spinraza%20for%20barn%200-18%20%C3%A5r.pdf Lest 8.5.2023."},{"key":"ref=5","unstructured":"Nye metoder. Spinraza til barn. https:\/\/nyemetoder.no\/nyheter\/spinraza-til-barn Lest 20.7.2023."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Mendell\u00a0JR, Al-Zaidy\u00a0S, Shell\u00a0R et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377: 1713\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29091557&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1706198","DOI":"10.1056\/NEJMoa1706198"},{"key":"ref=7","unstructured":"Mercuri\u00a0E, Deconinck\u00a0N, Mazzone\u00a0ES et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2022; 21: 42\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34942136&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(21)00367-7"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Yeo\u00a0CJJ, Simmons\u00a0Z, De Vivo\u00a0DC et al. Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann Neurol 2022; 91: 305\u201316. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34981567&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fana.26299","DOI":"10.1002\/ana.26299"},{"key":"ref=9","unstructured":"Magelssen\u00a0M, Rasmussen\u00a0M, Wallace\u00a0S et al. Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group. BMC Med Ethics 2021; 22: 54. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33947377&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12910-021-00623-5"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Magelssen\u00a0M, F\u00f8rde\u00a0R. Prioritering i helsetjenesten: Ni dilemmaer i kj\u00f8lvannet av Spinraza-saken. Nytt Norsk Tidsskrift 2018; 35: 279\u201388. Crossref: http:\/\/dx.doi.org\/10.18261%2Fissn.1504-3053-2018-03-04-08","DOI":"10.18261\/issn.1504-3053-2018-03-04-08"},{"key":"ref=11","unstructured":"Nye metoder. Beslutningsforum for nye metoder. https:\/\/nyemetoder.no\/Documents\/Beslutninger\/Beslutningsforum%2011042023_Protokoll.pdf Lest 20.7.2023."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Coratti\u00a0G, Pera\u00a0MC, Lucibello\u00a0S et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord 2020; 30: 756\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32900576&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.nmd.2020.07.005","DOI":"10.1016\/j.nmd.2020.07.005"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:53:14Z","timestamp":1781707994000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2023\/10\/kronikk\/start-og-stoppkriterier-svaert-dyre-medisiner-spinal-muskelatrofi-som-eksempel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":12,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.23.0346","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}